Overview

Classroom Study of SPN-812 in Children With ADHD

Status:
Withdrawn

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of SPN-812, an extended-release formulation of viloxazine, compared to placebo in children in an analog classroom setting.

Phase:

Phase 3

Details

Lead Sponsor:

Supernus Pharmaceuticals, Inc.